Application of the Rome severity classification of COPD exacerbations in a real-world cohort of hospitalised patients

Carmen Reumkens [1], Adrian Endres[2], Sami O. Simons [3], Paul H.M. Savelkoul[1], Roy T.M. Sprooten[4,6] and Frits M.E. Franssen [3,5,6]

[1]Department of Medical Microbiology, Infectious Diseases and Infection Prevention, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. [2]Department of Respiratory Medicine and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany. [3]Department of Respiratory Medicine, NUTRIM, MUMC+, Maastricht, The Netherlands. [4]Department of Respiratory Medicine, MUMC+, Maastricht, The Netherlands. [5]Department of Research and Education, Ciro, Horn, The Netherlands. [6]These authors contributed equally.

Corresponding author: Frits M.E. Franssen (fritsfranssen@ciro-horn.nl)

Abstract

Background Recently, the Rome classification was proposed in which objective and readily measurable variables were integrated to mark exacerbations of COPD (ECOPD) severity. The aim of this study is to investigate the distribution of a real-world patient population with hospitalised ECOPD according to the current classification across the newly proposed severity classification. We assume that a significant proportion of hospitalised patients will have a mild or moderate event.

Methods The Rome classification was applied to a cohort of 364 COPD patients hospitalised at the Department of Respiratory Medicine of Maastricht University Medical Center (MUMC) with a severe ECOPD. Differences in in-hospital, 30- and 90-day mortality were compared between mild, moderate and severe ECOPD according to the new classification. Moreover, data were stratified by the different severity classes and compared regarding general disease characteristics and clinical parameters.

Results According to the Rome proposal, 52 (14.3%) patients had a mild ECOPD, 204 (56.0%) a moderate and 108 (29.7%) a severe ECOPD. In-hospital mortality in mild, moderate and severe events was 3.8%, 6.9% and 13.9%, respectively. Most clinical parameters indicated a significantly worse condition in patients classified in the severe group, compared to those in mild or moderate groups.

Conclusion Most of the events, traditionally all classified as severe because of the hospitalisation, were classified as moderate, while almost 15% were mild. The results of this study provide insight into the heterogeneity of hospitalised ECOPD and show that the newly proposed Rome criteria can differentiate between events with different short-term mortality rates.

Introduction

COPD is the most prevalent chronic respiratory disease worldwide and is associated with significant health and economic burden. Despite available treatments, COPD cannot be cured, and it is one of the major leading causes of death across the globe [1]. A significant proportion of patients with COPD suffer from exacerbations (ECOPD), which are traditionally defined as an acute worsening of respiratory symptoms resulting in additional therapy [2]. ECOPD contribute to lung function deterioration [3], poor health status [4, 5], deconditioning [6] and premature mortality [7]. The vast majority of ECOPD is treated in the outpatient setting, but hospitalisation may be warranted in severe events [8] and these are associated with even worse outcomes [7]. According to the traditional severity classification for ECOPD, mild events are those treated with short-acting bronchodilators (SABDs); moderate events require antibiotics, systemic corticosteroids or both; and severe events are those requiring admission to an emergency room or hospitalisation [2]. Thus, severity of ECOPD is usually graded *post hoc*, based on what medications were

used to control symptoms and in what setting [2]. As management of ECOPD may differ according to local protocols and financing of care, and availability and access to healthcare, clinical heterogeneity within each of the three severity ECOPD classes is anticipated. For example, the absence of family caregivers or severe anxiety associated with increased dyspnoea may contribute to an indication for hospitalisation and therefore the classification of the ECOPD as severe, irrespective of objective measures of respiratory status. Furthermore, different hospitals, physicians and patients may have different individual preferences or habits that influence treatment decisions, especially across the globe and cultures.

Recently, a new severity classification of ECOPD was proposed by a group of international COPD experts [9]. In this new classification, named the Rome proposal, six objectively measured variables are used to mark the event severity: dyspnoea (assessed by a visual analogue scale (VAS) [10] (on a scale of 0–10) $\geqslant 5$), arterial oxygen saturation (S_{aO_2}), respiratory rate, heart rate, serum C-reactive protein (CRP) and, in selected cases, arterial blood gases (ABG). Based on these variables, ECOPD are subsequently classified as mild (low dyspnoea, low breathing rate, low heart rate, normal S_{aO_2}, low CRP), moderate (three of the following: high dyspnoea, high respiratory rate, high heart rate, low S_{aO_2}, high CRP) or severe (hypercapnia and acidosis) (supplementary table S1) [9].

The distribution of a real-world population of patients with ECOPD according to the traditional classification across the newly proposed severity classification is currently unknown. Resulting from the lack of objective criteria in the traditional classification, we assume that a significant proportion of hospitalised patients will have a mild or moderate event according to the Rome classification. Moreover, in-hospital, 30- and 90-day mortality of patients stratified according to the Rome severity classification is unknown. This may have important implications for the clinical implementation of this new classification, for the perception of these events by patients and healthcare workers, for the impact on healthcare costs and for the interpretation of clinical COPD studies using severe ECOPD as an outcome. The aim of this study is therefore to apply the Rome severity classification to a real-world population of patients with hospitalised ECOPD according to the traditional classification and, subsequently, compare the clinical implementation of the two classifications.

Methods

The present study concerns a *post hoc* analysis on a previously published study in which data from a real-world cohort of COPD patients hospitalised with a severe ECOPD were used to develop a risk stratification tool for severe ECOPD [11]. In the current study, the Rome severity classification was applied to this cohort, which consisted of 364 patients admitted to the Department of Respiratory Medicine of Maastricht University Medical Center (MUMC), the Netherlands, between 1 June 2011 and 31 December 2014. Demographics, vital and physical signs, laboratory results, ABG and phenotypic disease characteristics were available for all patients. Moreover, in-hospital and 30- and 90-day all-cause mortality were recorded. Patient identification as well as inclusion and exclusion criteria were previously described [11] Because of the use of de-identified clinical data, ethical approval was not necessary according to the local ethical committee (METC 13-4-041).

Study design

First, the Rome criteria were applied to the cohort. Since severe dyspnoea (VAS $\geqslant 5$) is the most common symptom in patients hospitalised for ECOPD [12, 13] and is generally considered the most relevant symptom for most cases of ECOPD [9] and no VAS was available to quantify dyspnoea in this cohort, a positive score for this item of the severity classification was assumed in all patients. Moreover, differences in in-hospital, 30- and 90-day mortality were compared between mild, moderate and severe ECOPD according to the new classification. Thereafter, the different severity classes were compared regarding general disease characteristics and clinical parameters.

Statistical analysis

Statistical analysis was performed with IBM SPSS version 28.0 software for Windows (IBM Corporation, Armonk, NY, USA). First descriptive analysis was performed. Thereafter a frequency distribution was generated through applying the Rome severity classification to this COPD cohort. Moreover, data were stratified by the different severity classes and compared regarding general disease characteristics and clinical parameters. Variables were subjected to the Shapiro–Wilk normality test. For normally distributed variables, one-way ANOVA followed by Tukey's test was performed to indicate differences between severity classes. For non-parametric data, Kruskal–Wallis followed by Dunn's with a Bonferroni correction for multiple comparison was applied. Categorical variables were compared using Pearson's Chi-squared test or the Fisher's exact test, as appropriate, followed by Bonferroni adjustment. p-values of <0.05 were considered to indicate statistical significance.

TABLE 1 Demographics and clinical characteristics of 364 patients admitted to hospital with an exacerbation of COPD (ECOPD) prior to admission	
Age years	70.5±10.2
Age ⩾80 years	79 (21.7)
Sex, male	169 (46.4)
Current smoker	132 (37.0)
GOLD stage	
1. FEV$_1$ ⩾80%	10 (2.7)
2. 50%⩽FEV$_1$<80%	119 (32.7)
3. 30%⩽FEV$_1$<50%	170 (46.7)
4. FEV$_1$ <30%	65 (17.9)
Comorbidities: Charlson's index	2.22±1.44
Supported living and extra care	185 (53.0)
Cohabiting	196 (59.0)
Residence status	
Own home	292 (83.2)
Retirement home	47 (13.4)
Other	12 (3.4)
Previous admission ever	204 (56.0)
Admission last 2 years	
0	203 (55.8)
1	89 (24.4)
2	35 (9.6)
⩾3	37 (10.2)

Data are reported as n (%) or mean±SD. GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV$_1$: forced expiratory volume in 1 s.

Results

Characteristics of hospitalised ECOPD cohort

As presented in table 1, the study population consisted of an almost even distribution of elderly male and female patients. A substantial proportion were current smokers. The majority of patients had severe airflow limitation. More than half of the population needed support and extra care with daily living, while most lived in their own home. Moreover, >50% of patients were previously admitted to the hospital with an ECOPD, whereas almost one in four had a previous admission for an ECOPD in the last 2 years.

Application of Rome severity classification to patient cohort hospitalised with ECOPD

The traditional severity classification categorises the severity of ECOPD of all 364 patients as severe, as they all were hospitalised due to the event. In contrast, when implementing the criteria of the Rome proposal, 52 (14.3%) patients had a mild ECOPD, 204 (56.0%) patients a moderate and 108 (29.7%) patients a severe ECOPD (table 2). In addition, out of 31 patients who died in hospital 14 (3.8%) patients had a moderate ECOPD, while 15 (4.1%) patients were classified as severe. Thus, in-hospital mortality in mild, moderate and severe events was 3.8%, 6.9% and 13.9%, respectively. The proportion of patients that died at days 30 and 90 was highest in the group of severe ECOPD, but deaths were also observed in the

TABLE 2 Stratification of the Rome severity classification across a hospitalised COPD cohort with exacerbations of COPD (ECOPD)				
	Rome classification			Traditional
	Mild	Moderate	Severe	
Patients n	52	204	108	364
Deceased in-hospital	2 (0.5)	14 (3.8)	15 (4.1)	31 (8.5)
30-day mortality	4 (1.1)	15 (4.1)	19 (5.2)	38 (10.4)
90-day mortality	4 (1.1)	28 (7.7)	27 (7.4)	59 (16.2)
Cohabiting (N=47/187/98)	26 (7.1)	117 (32.1)	53 (14.6)	196 (53.8)
Supported living (N=49/196/104)	24 (6.6)	98 (26.9)	63 (17.3)	185 (50.8)

Data are presented as n (%). Percentage is calculated out of total number of patients (N=364).

TABLE 3 Criteria for determining exacerbation of COPD (ECOPD) severity according to the Rome proposal

Criteria (n)	Mild	Moderate	Severe	p-value[¶]
Dyspnoea[#] (N=52/204/108)	52 (100.0)	204 (100.0)	108 (100.0)	
HR beats·min^{-1}	84.3±16.2	101.3±18.0	106.9±24.2	<0.001
HR ⩾95 (N=51/200/106)	6 (11.8)	133 (66.5)	74 (69.8)	
RR breaths·min^{-1}	19.0±4.3	24.9±5.2	26.9±7.0	<0.001
RR ⩾24 (N=14/99/60)	2 (14.3)	69 (69.7)	42 (70.0)	
Resting S_{aO_2} %	89.2±6.7	86.8±6.0	83.2±11.1	<0.001
S_{aO_2} <92% (N=48/203/106)	21 (43.8)	163 (80.3)	86 (81.1)	
CRP levels mg·L^{-1}	20.0±33.4	81.3±86.6	75.7±98.0	<0.001
CRP ⩾10 (N=51/203/107)	17 (33.3)	178 (87.7)	79 (73.8)	
ABG P_{aO_2} mmHg	66.8±25.9	57.0±12.6	66.3±35.0	0.022
P_{aO_2} ⩽60 (N=48/203/107)	18 (37.5)	136 (67.0)	57 (53.3)	
ABG P_{aCO_2} mmHg	45.4±9.7	45.0±12.4	69.5±18.2	<0.001
P_{aCO_2} >45 (N=51/203/108)	22 (43.1)	82 (40.4)	102 (94.4)	
pH	7.42±0.04	7.42±0.04	7.26±0.07	<0.001
pH <7.35 (N=51/203/108)			108 (100.0)	
Number of positive criteria	1.88±0.32	3.66±0.68	3.60±0.98	

Data are presented as n (%) and mean±SD, unless otherwise stated. HR: heart rate; RR: respiratory rate; S_{aO_2}: oxygen saturation measured in arterial blood gas; CRP: C-reactive protein; ABG: arterial blood gas; P_{aO_2}: arterial oxygen tension; P_{aCO_2}: arterial carbon dioxide tension. [#]: the dyspnoea score was missing in the database; a positive score of this item was assumed in all patients. [¶]: Kruskal–Wallis test.

mild and moderate events (30 days: mild 7.7%, moderate 7.4%, severe 17.6%; 90 days: mild 7.7%, moderate 13.7%, severe 25.0%). Almost half of the population lived on their own, and especially patients in the severe group (60.5%) received extra care.

Rome proposal criteria and clinical characteristics stratified by ECOPD severity

The results for the individual items of the newly proposed Rome criteria for the three different severity classes are shown in table 3. As mentioned in the methods, it was assumed that all hospitalised patients suffered from severe dyspnoea. Except for serum CRP, mean values of all parameters indicated a significantly worse condition in patients classified in the severe group, compared to those in mild or moderate groups. According to the Rome proposal, acidosis and hypercapnia are the two criteria to indicate a severe ECOPD. Our analysis shows that both were statistically different from mild and moderate events (p<0.001). Mean heart rate, respiratory rate, CRP and S_{aO_2} levels for mild events were significantly different from those of moderate and severe events (supplementary table S2). Except for arterial carbon dioxide tension (P_{aCO_2}) and pH, the mean value of the other variables did not differentiate between moderate and severe ECOPD.

Table 4 shows demographics, lung function, comorbidities and other clinical and laboratory parameters for patients stratified according to the Rome classification. Age, sex distribution, body mass index (BMI) and smoking status were comparable between groups. >50% of patients in the three severity categories were previously admitted to hospital during their lifetime, of which patients with a mild ECOPD had the highest comorbid index. Results from spirometry, body box and diffusion measurements differed between groups; especially, results from forced expiratory volume in 1 s (FEV$_1$) and FEV$_1$ % pred for the severe group were significantly lower compared to mild and moderate ECOPD (supplementary table S3). Additionally, it was apparent that a significantly higher proportion of patients with a severe ECOPD were in need of extra oxygen while being hospitalised. Lastly, radiological abnormalities were more frequently observed in patients classified as severe (supplementary table S3).

Discussion

This study showed that only a minority of patients hospitalised with ECOPD fulfilled the newly proposed Rome criteria for a severe event. Most of the events, traditionally all classified as severe because of the hospitalisation, were classified as moderate, while almost 15% were mild. In-hospital and post-discharge mortality were highest in patients with severe ECOPD, although >10% of patients with mild to moderate ECOPD died within 90 days after hospitalisation. Patients with severe ECOPD had more severe underlying COPD and received more extra care. The latter indicates a higher burden of disease prior to the ECOPD. Those with mild ECOPD were slightly older and had more comorbidities. It can be speculated that these

TABLE 4 Clinical parameters stratified by Rome severity classification

Characteristics (n)	Mild	Moderate	Severe	p-value[#]
Age	72.8±10.0	70.2±10.3	70.1±10.0	0.221[¶]
Sex, male (N=52/204/108)	27 (51.9)	90 (44.1)	52 (48.1)	0.549
BMI kg·m^{-2}	24.4±5.2	25.2±6.2	24.8±7.2	0.608
Smoking status current smoker (N=51/202/104)	21 (41.2)	69 (34.2)	42 (40.4)	0.451
GOLD stage (N=52/204/108)				
1. FEV_1 ⩾80%	3 (5.8)	7 (3.4)		0.056[+]
2. 50% ⩽FEV_1<80%	21 (40.4)	70 (34.4)	28 (25.9)	
3. 30% ⩽FEV_1<50%	20 (38.5)	95 (46.6)	55 (50.9)	
4. FEV_1 <30%	8 (15.4)	32 (15.7)	25 (23.1)	
Lung function				
FEV_1 L	1.2±0.5	1.1±0.5	0.9±0.3	0.004
FEV_1 % pred	50.4±19.7	46.4±17.2	40.5±12.9	0.004
FEV_1/FVC	45.3±12.8	41.9±12.0	39.1±10.5	0.013
Diffusion				
D_{LCO}/SB % pred	47.7±19.1	49.4±18.3	40.8±15.1	0.009
Previous admission				
Admission ever (N=52/204/108)	26 (50.0)	118 (57.8)	60 (55.6)	0.592
Admission last 2 years (N=52/204/108)				
0	31 (59.6)	107 (52.5)	65 (60.2)	0.354
1	8 (15.4)	61 (29.9)	20 (18.5)	0.342
2	5 (9.6)	20 (9.8)	10 (9.3)	
⩾3	8 (15.4)	16 (7.8)	13 (12.0)	
Comorbidities: Charlson's index	2.65±1.6	2.08±1.3	2.28±1.5	0.035
CCI category				
CCI 1–2 points (N=52/204/108)	30 (57.7)	143 (70.1)	72 (66.7)	0.231
CCI ⩾3 points (N=52/204/108)	22 (42.3)	61 (29.9)	36 (33.3)	
Vital signs				
Temperature °C	36.9±0.7	37.5±0.9	37.0±1.1	<0.001
Systolic BP mmHg	140.8±26.5	137.9±25.0	145.6±28.3	0.070
Diastolic BP mmHg	77.2±17.0	75.1±15.7	79.8±16.7	0.106
Extra F_{IO_2} (N=46/177/91)	16 (34.8)	68 (38.4)	58 (63.7)	<0.001
Physical examination				
Confused (N=2/15/10)	1 (50.0)	3 (20.0)	4 (40.0)	0.338[+]
Use of accessory muscles (N=3/15/16)	1 (33.3)	14 (93.3)	15 (93.8)	0.031[+]
Elevated CVP (N=20/62/37)	2 (10.0)	7 (11.3)	11 (29.7)	0.050[+]
Peripheral oedema (N=42/180/85)	12 (28.6)	47 (26.1)	29 (34.1)	0.404
Wheezing (N=50/202/108)	36 (72.0)	63 (31.2)	56 (51.9)	0.056
Crackles (N=50/202/108)	13 (26.0)	63 (31.2)	39 (36.1)	0.421
Blood eosinophils %	1.3±2.1	0.7±1.6	1.4±2.4	0.107
Troponin >14 ng·L^{-1} (N=52/204/108)	7 (13.5)	48 (23.5)	34 (31.5)	0.041
NT-proBNP pmol·L^{-1}	323.7±582.6	405.9±621.4	518.7±678.1	0.057
NT-proBNP ⩾500 pmol·L^{-1} (N=17/73/49)	2 (11.8)	13 (17.8)	16 (32.7)	0.105[+]
Chest radiograph				
Consolidation (N=51/204/108)	5 (9.8)	69 (33.8)	33 (30.6)	0.003
Signs of congestion (N=51/204/108)	3 (5.9)	23 (11.3)	26 (24.1)	0.002
ECG				
Atrial fibrillation (N=47/183/99)	6 (12.8)	20 (10.9)	17 (17.2)	0.332
Signs of ischaemia (N=47/183/99)	2 (4.3)	10 (5.5)	10 (10.1)	0.272[+]

Data are presented as n (%) or mean±SD, unless otherwise stated. BMI: body mass index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FEV_1: forced expiratory volume in 1 s; FEV_1/FVC: FEV_1/forced vital capacity ratio; D_{LCO}/SB: single-breath diffusing capacity of the lung for carbon monoxide; CCI: Charlson's comorbidity index; BP: blood pressure; F_{IO_2}: fraction of inspired oxygen; NT-proBNP: N-terminal pro-brain natriuretic peptide; ECG: electrocardiogram; % pred: percentage of predicted value. [#]: Kruskal–Wallis test unless otherwise stated; [¶]: one-way ANOVA; [+]: Fisher's exact test.

factors contributed to the indication for hospitalisation in these milder ECOPD. The results of this study provide insight into the heterogeneity of hospitalised ECOPD and show that the newly proposed Rome criteria can differentiate between events with different short-term mortality rates.

It is well acknowledged that the traditional severity classification of ECOPD results in substantial variability in clinical characteristics of patients with hospitalised events. This hinders the interpretation of interventional studies which use hospitalisations as an outcome and the efforts to study the pathophysiology and predictors of ECOPD within the hospital setting. The Rome classification resulted from a Delphi process during which a group of international COPD experts selected six measured variables as markers of event severity, based on thorough literature review and discussion. The implementation of objective, easy and ready to measure variables in this proposed classification may contribute to a better delineation of clinically different ECOPD. Also, this may aid in differentiating ECOPD from other conditions with similar symptoms. Indeed, differences in comorbidities and radiologic abnormalities between severity classes were observed in the current study. Moreover, implementation of these criteria may facilitate clinical decision-making if it can be demonstrated that objectively identified mild and/or moderate events are associated with better outcomes than severe ECOPD. Ultimately, these criteria could be used as a basic set for reimbursement of costs related to hospitalisations.

As expected, heart rate and respiratory rate were significantly elevated in patients with a moderate and severe ECOPD compared to patients with a mild event, since the Rome classification is largely based on differences in these parameters. Several studies showed that both an elevated heart rate [14–16] and respiratory rate [17–19] were predictive variables for the severity of an ECOPD. JENSEN et al. [20] showed that an increase in resting heart rate is associated with severity of COPD and correspondingly mortality risk. These two variables are easily and noninvasively measured, and of great value in grading the respiratory status and, with that, ECOPD severity [15, 21–23]. Serum CRP values were highest during moderate events, with 87.7% of patients having a CRP above 10 mg·L^{-1}. Although measuring CRP levels as a marker of airway inflammation may lack specificity, it is widely recognised as a useful and sensitive marker of infections and ECOPD [24]. The current analysis suggests that a cut-off value of 10 mg·L^{-1} lacks sensitivity to distinguish between moderate and severe events. Also, clinical parameters were largely comparable between events characterised as moderate or severe. This suggests that the Rome classification mainly enables differentiation between mild and more severe ECOPD. Furthermore, this study showed that patients with a severe ECOPD demonstrated lower S_{aO_2} levels: 81.1% of patients had a S_{aO_2} <92%. This corresponds to other studies which showed that a reduction in S_{aO_2} was associated with ECOPD risk [14–16]. It should be noted that the extent of change is important for early ECOPD detection. The Rome proposal uses a change of 3% to distinguish mild from moderate events. More studies are needed to pinpoint the correct change in S_{aO_2} to assess ECOPD risk. Additionally, ABG showed hypercapnia in 94.4% of patients and acidosis in all patients during a severe episode. These are mostly serious complications observed in patients in the advanced phase of COPD [25], where the lower the pH the higher the mortality risk [26–28]. While measuring ABG is more reliable than pulse oximetry, it is less practical and not widely available in all clinical settings.

As for the clinical parameters, it was apparent that general characteristics such as age, sex, smoking status and BMI did not significantly differ in our analysis between the different severities. Identifying the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage of patients mostly offers clinicians valuable information to implement appropriate treatment. Results from routine lung function tests were significantly different between the three ECOPD severities. Nonetheless, a great number of patients are not able to complete pulmonary function testing because of their poor health conditions [29]. Furthermore, several biomarkers such as blood eosinophilia, troponin and NT-proBNP levels were elevated for patients having a severe event. Eosinophil levels have until now not been used to determine ECOPD severity but can give an indication of whether systemic corticosteroids should be given to treat a patient [30]. Troponin and N-terminal pro-brain natriuretic peptide (NT-proBNP) are mainly associated with heart failure, which can be a confounding comorbidity or may coexist with an ECOPD [9, 31]. Another inflammatory mediator that is associated with ECOPD are neutrophils, as ECOPD are an acute burst of local or systemic inflammatory mediators [29]. These cells are the most abundant inflammatory cells found in blood and sputum. Numbers increase while having an ECOPD and could therefore be a valuable parameter to indicate severity [32, 33].

Our analysis shows that significantly more patients with a severe ECOPD received extra oxygen while being hospitalised compared to patients with a mild or moderate event. This can be a valuable additional marker to indicate event severity. In a larger number of cases, chest radiograph showed signs of congestion and consolidation in the moderate and severe group. This suggests that other clinical conditions including heart failure and pneumonia complicate the ECOPD and contribute to event severity. While it could be

argued that these patients did not have a strict diagnosis of ECOPD, these results reflect the real-life clinical setting of the studied cohort. As such, the presence of other acute conditions could be added to a severity classification for ECOPD. The current study also suggests that it is important to perform additional clinical evaluations, imaging and biomarker measurements to diagnose other conditions [34, 35].

This study has several limitations that need to be addressed. First, data from this clinical COPD cohort were obtained from a single centre in the Netherlands, meaning that the results are probably different for other COPD populations, hospitals or healthcare settings/systems with different disease severity assessments and protocols for hospitalisation and management of ECOPD. Also, the cohort only included hospitalised patients, so the potential contribution of the Rome criteria in clinical decision-making regarding hospitalisation or not at the emergency room remains unknown. The assumption of VAS $\geqslant 5$ resulted in a minimum of one positive criterium in all patients and a shift towards more moderate events. Several other studies in patients hospitalised for ECOPD indicated that severe dyspnoea is indeed the most important symptom in this setting [12, 13], supporting the assumption of the current study. Also, this assumption did not affect the proportion of patients with severe ECOPD as VAS has no criterium for that. The change of 3% in resting S_{aO_2} for mild *versus* moderate events and the time frame for development of symptoms (within 14 days according to the Rome definition experts [9]) were not determined, and therefore not included in our analyses. Lastly, this study is partly focused on the relationship between ECOPD severity and 30- and 90-day in-hospital mortality. Data on mortality for a longer time period were not available for this study. Hospital readmission is also an important outcome parameter that can influence ECOPD severity and, subsequently, mortality. Data for this were not available but should be taken into account in future studies.

The traditional severity classification has several shortcomings that may negatively affect clinical and healthcare decisions. The current Rome criteria are all readily measurable and provide objective measurements of symptoms, signs, biomarkers and physiological variables. However, according to data from the Azithromycin for Acute Exacerbations Requiring Hospitalisation (BACE) study [36], three moderate criteria were met by 70% of hospitalised patients due to an ECOPD, four moderate criteria by 36.4% and five criteria by 6.9%. Only 8.3% of patients met the criteria belonging to a severe event. In the current analysis, most ECOPD were classified as moderate and almost 30% as severe. RAMAKRISHNAN *et al.* [37] stressed that the different endotypes of ECOPD severity cannot be assessed by solely focusing on inflammatory and pathophysiological parameters. Interestingly, the current results showed that a remarkably high percentage (>10%) of patients with a mild to moderate event died within 30 or 90 days after hospitalisation. This raises questions as to whether an ECOPD can be interpreted as either mild or moderate, instead of severe. Nevertheless, it is known that the main causes of death in mild and moderate COPD are lung cancer or cardiovascular diseases [38]. From our analysis, patients with a mild ECOPD showed the highest comorbid index, which could indicate that they have been hospitalised because of their comorbidity rather than the severity of their acute respiratory event. Therefore, it can be debated whether merely the Rome criteria can be used as an indicator for hospitalisation of ECOPD. In more severe COPD, respiratory failure is the primary cause [38]. Next to comorbidities and acute respiratory failure, the GOLD 2023 strategy document states that other potential indications for hospitalisation could be the onset of new physical signs such as cyanosis and peripheral oedema, failure of an acute ECOPD to respond to initial medical management and insufficient home support [2]. These are currently not considered in the Rome classification.

Until now, there exists no universal marker to specify an ECOPD, and with that ECOPD cause. Clinical parameters such as GOLD stage, eosinophil or neutrophil levels and receiving extra oxygen could be integrated as additional criteria to assess ECOPD occurrence and severity. It is important to consider COPD as a multicomponent disease and take all-cause mortality as one of the major end-points in order to apply appropriate therapy. The Rome proposal criteria are the first step to differentiate between clinically different ECOPD, which may in turn be of value in differentiating ECOPD from other conditions with similar symptoms. In addition, the traditional grading of ECOPD severity is merely based on medication use and hospitalisations and thus required refinement. The implementation of objective variables in the newly proposed severity classification will better inform clinical and healthcare decisions as well as the interpretation of results in research. Although the Rome proposal may still need refinement in selection of variables and corresponding thresholds, this study provided important initial insights into the distinctive and predictive value of the proposed classification and is an important step towards a change in the traditional ECOPD severity classification.

References

1 GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med* 2020; 8: 585–596.

2 World Health Organization (WHO). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2023 report. https://goldcopd.org/2023-gold-report-2/

3 Hoogendoorn M, Feenstra TL, Hoogeveen RT, *et al.* Association between lung function and exacerbation frequency in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2010; 5: 435–444.

4 Seemungal TA, Donaldson GC, Paul EA, *et al.* Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998; 157: 1418–1422.

5 Miravitlles M, Ferrer M, Pont A, *et al.* Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. *Thorax* 2004; 59: 387–395.

6 Decramer M, Rennard S, Troosters T, *et al.* COPD as a lung disease with systemic consequences: clinical impact, mechanisms, and potential for early intervention. *COPD* 2008; 5: 235–256.

7 Rothnie KJ, Mullerova H, Smeeth L, *et al.* Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2018; 198: 464–471.

8 Bahadori K, FitzGerald JM. Risk factors of hospitalization and readmission of patients with COPD exacerbation: systematic review. *Int J Chron Obstruct Pulmon Dis* 2007; 2: 241–251.

9 Celli BR, Fabbri LM, Aaron SD, *et al.* An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. *Am J Respir Crit Care Med* 2021; 204: 1251–1258.

10 Wilkinson TMA, Aris E, Bourne S, *et al.* A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. *Thorax* 2017; 72: 919–927.

11 Sprooten RT, Rohde GG, Lawyer G, *et al.* Risk stratification for short-term mortality at hospital admission for acute exacerbations of COPD. *Respirology* 2019; 24: 765–776.

12 Pinto-Plata VM, Livnat G, Girish M, *et al.* Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. *Chest* 2007; 131: 37–43.

13 Noell G, Cosio BG, Faner R, *et al.* Multi-level differential network analysis of COPD exacerbations. *Eur Respir J* 2017; 50: 1700075 .

14 Martín-Lesende I, Orruño E, Bilbao A, *et al.* Impact of telemonitoring home care patients with heart failure or chronic lung disease from primary care on healthcare resource use (the TELBIL study randomised controlled trial). *BMC Health Services Research* 2013; 13: 1–15.

15 Hurst JR, Donaldson GC, Quint JK, *et al.* Improved adherence with once daily *versus* twice daily dosing of mometasone furoate administered *via* a dry powder inhaler: a randomized open label study. *BMC Pulm Med* 2010; 10: 1–11.

16 Burton C, Pinnock H, McKinstry B. Changes in telemonitored physiological variables and symptoms prior to exacerbations of chronic obstructive pulmonary disease. *J Telemed Telecare* 2015; 21: 29–36.

17 Yañez AM, Guerrero D, de Alejo RP, *et al.* Monitoring breathing rate at home allows early identification of COPD exacerbations. *Chest* 2012; 142: 1524–1529.

18 Borel J-C, Pelletier J, Taleux N, *et al.* Parameters recorded by software of non-invasive ventilators predict COPD exacerbation: a proof-of-concept study. *Thorax* 2015; 70: 284–285.

19 Flattet Y, Garin N, Serratrice J, *et al.* Determining prognosis in acute exacerbation of COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 467–475.

20 Jensen MT, Marott JL, Lange P, *et al.* Resting heart rate is a predictor of mortality in COPD. *Eur Respir J* 2013; 42: 341–349.

21 Tseng C-Y, Chang JC-Y, Chen Y-C, *et al.* Changes of heart rate variability predicting patients with acute exacerbation of chronic obstructive pulmonary disease requiring hospitalization after emergency department treatment. *J Chin Med Assoc* 2018; 81: 47–52.

22 Elvekjaer M, Aasvang EK, Olsen RM, *et al.* Physiological abnormalities in patients admitted with acute exacerbation of COPD: an observational study with continuous monitoring. *J Clin Monit Comput* 2020; 34: 1051–1060.

23 Rubio N, Parker RA, Drost EM, *et al.* Home monitoring of breathing rate in people with chronic obstructive pulmonary disease: observational study of feasibility, acceptability, and change after exacerbation. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1221–1231.

24 Dev D, Wallace E, Sankaran R, *et al.* Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. *Respir Med* 1998; 92: 664–667.

25 Bruno CM, Valenti M. Acid-base disorders in patients with chronic obstructive pulmonary disease: a pathophysiological review. *J Biomed Biotechnol* 2012; 2012: 915150.

26 Onadeko B, Khadadah M, Abdella N, *et al.* Prognostic factors in the management of exacerbation of chronic obstructive pulmonary disease in Kuwait. *Med Princ Pract* 2005; 14: 35–40.

27 Budweiser S, Jörres RA, Riedl T, *et al.* Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. *Chest* 2007; 131: 1650–1658.

28 Ucgun I, Oztuna F, Dagli CE, *et al.* Relationship of metabolic alkalosis, azotemia and morbidity in patients with chronic obstructive pulmonary disease and hypercapnia. *Respiration* 2008; 76: 270–274.

29 Chen J, Yang Z, Yuan Q, *et al.* Prediction of gold stage in patients hospitalized with COPD exacerbations using blood neutrophils and demographic parameters as risk factors. *BMC Pulm Med* 2021; 21: 329.

30 Bafadhel M, Greening NJ, Harvey-Dunstan TC, *et al.* Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. *Chest* 2016; 150: 320–328.

31 Neder JA, Rocha A, Alencar MCN, *et al.* Current challenges in managing comorbid heart failure and COPD. *Expert Rev Cardiovasc Ther* 2018; 16: 653–673.

32 Lonergan M, Dicker AJ, Crichton ML, *et al.* Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. *Respir Res* 2020; 21: 1–10.

33 Milara J, Juan G, Peiró T, *et al.* Neutrophil activation in severe, early-onset COPD patients *versus* healthy non-smoker subjects *in vitro*: effects of antioxidant therapy. *Respiration* 2012; 83: 147–158.

34 Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. *Eur Respir J* 2009; 33: 1165–1185.

35 Recio Iglesias J, Díez-Manglano J, López García F, *et al.* Management of the COPD patient with comorbidities: an experts recommendation document. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 1015–1037.

36 Vermeersch K, Gabrovska M, Aumann J, *et al.* Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE). A multicenter, randomized, double-blind, placebo-controlled trial. *Am J Respir Crit Care Med* 2019; 200: 857–868.

37 Ramakrishnan S, Gyselinck I, Bafadhel M, *et al.* Chronic obstructive pulmonary disease exacerbations: do all roads lead to Rome? *Am J Respir Crit Care Med* 2022; 205: 1125–1126.

38 Sin DD, Anthonisen NR, Soriano JB, *et al.* Mortality in COPD: role of comorbidities. *Eur Respir J* 2006; 28: 1245–1257.